Targeting Diphtheria Toxin and TNF Alpha Expression in Ovarian Tumors Using the H19 Regulatory Sequences

Overview

Journal Int J Clin Exp Med

Specialty General Medicine

Date 2010 Nov 13

PMID 21072261

Citations 6

Authors

Aya Mizrahi

Abraham Hochberg

Smadar Amiur

Jennifer Gallula

Imad Matouk

Tatiana Birman

Tally Levy

Sorin Ladimir

Patricia Ohana

Affiliations

Soon will be listed here.

Abstract

Background: There are currently no effective therapies for the treatment of ovarian cancer ascites fluid (OCAF). H19 is an RNA oncofetal gene that is present at high levels in human cancer tissues (ovarian cancer and OCAF among them), while existing at a nearly undetectable level in the surrounding normal tissue. There is evidence for a synergistic effect in cell cytotoxicity mediated by TNFα and diphtheria toxin in sensitive and resistant human ovarian tumor cell line. Thus, we tested the cytotoxic effect of TNF-α cytokine, together with the diphtheria toxin, in the therapy of ovarian cancer.

Methods: The therapeutic potential of toxin vectors carrying the DT-A gene alone (pH19-DTA), or in combination with the TNF-α gene (pH19-TNF-DTA), driven by H19 regulatory sequences were tested in ovarian carcinoma cell lines and in a heterotopic ovarian cancer model.

Results: The toxin vectors showed a high killing capacity when transfected into different ovarian cancer cell lines. In addition, intratumoral injection of the toxin vector into ectopically developed tumors caused 40% inhibition of tumor growth. The killing effect after injection of pH19-TNF-DTA plasmid into ectopically developed tumors was significantly higher than that showed by the pH19-DTA plasmid alone, particularly in diphtheria toxin and TNF resistant tumors.

Conclusions: These observations may be the first step towards a major breakthrough in the treatment of human ovarian cancer. It should enable us to identify likely non-responders in advance, and to treat patients who are resistant to all known therapies, thereby avoiding treatment failure coupled with unnecessary suffering and cost.

Citing Articles

Targeted Diphtheria Toxin-Based Therapy: A Review Article.

Shafiee F, Aucoin M, Jahanian-Najafabadi A Front Microbiol. 2019; 10:2340.

PMID: 31681205 PMC: 6813239. DOI: 10.3389/fmicb.2019.02340.

The Role of Long Non-Coding RNAs in Ovarian Cancer.

Nikpayam E, Tasharrofi B, Sarrafzadeh S, Ghafouri-Fard S Iran Biomed J. 2016; 21(1):3-15.

PMID: 27664137 PMC: 5141251. DOI: 10.6091/.21.1.24.

An overview of long non-coding RNAs in ovarian cancers.

Meryet-Figuiere M, Lambert B, Gauduchon P, Vigneron N, Brotin E, Poulain L Oncotarget. 2016; 7(28):44719-44734.

PMID: 26992233 PMC: 5190131. DOI: 10.18632/oncotarget.8089.

Efficient Inhibition of Ovarian Cancer by Gelonin Toxin Gene Delivered by Biodegradable Cationic Heparin-polyethyleneimine Nanogels.

Bai Y, Gou M, Yi T, Yang L, Liu L, Lin X Int J Med Sci. 2015; 12(5):397-406.

PMID: 26005374 PMC: 4441064. DOI: 10.7150/ijms.10929.

Killing of cancer cells through the use of eukaryotic expression vectors harbouring genes encoding nucleases and ribonuclease inhibitor.

Glinka E Tumour Biol. 2015; 36(5):3147-57.

PMID: 25874497 DOI: 10.1007/s13277-015-3360-z.

References

Ohana P, Bibi O, Matouk I, Levy C, Birman T, Ariel I . Use of H19 regulatory sequences for targeted gene therapy in cancer. Int J Cancer. 2002; 98(5):645-50. DOI: 10.1002/ijc.10243. View

Sidi A, Ohana P, Benjamin S, Shalev M, Ransom J, Lamm D . Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin. J Urol. 2008; 180(6):2379-83. DOI: 10.1016/j.juro.2008.08.006. View

Ohana P, Kopf E, Bibi O, Ayesh S, Schneider T, Laster M . The expression of the H19 gene and its function in human bladder carcinoma cell lines. FEBS Lett. 1999; 454(1-2):81-4. DOI: 10.1016/s0014-5793(99)00780-2. View

Jandu N, Richardson M, Singh G, Hirte H, Hatton M . Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property. Int J Gynecol Cancer. 2006; 16(4):1536-44. DOI: 10.1111/j.1525-1438.2006.00624.x. View

Mizrahi A, Czerniak A, Levy T, Amiur S, Gallula J, Matouk I . Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences. J Transl Med. 2009; 7:69. PMC: 2734756. DOI: 10.1186/1479-5876-7-69. View

Ariel I, Sughayer M, Fellig Y, Pizov G, Ayesh S, Podeh D . The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. Mol Pathol. 2001; 53(6):320-3. PMC: 1186987. DOI: 10.1136/mp.53.6.320. View

Tanos V, Prus D, Ayesh S, Weinstein D, Tykocinski M, de-Groot N . Expression of the imprinted H19 oncofetal RNA in epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 1999; 85(1):7-11. DOI: 10.1016/s0301-2115(98)00275-9. View

Kulbe H, Thompson R, Wilson J, Robinson S, Hagemann T, Fatah R . The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 2007; 67(2):585-92. PMC: 2679985. DOI: 10.1158/0008-5472.CAN-06-2941. View

Morimoto H, Safrit J, Bonavida B . Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines. J Immunol. 1991; 147(8):2609-16. View

10.

Cannistra S . Cancer of the ovary. N Engl J Med. 2004; 351(24):2519-29. DOI: 10.1056/NEJMra041842. View

11.

Maxwell I, Glode L, Maxwell F . Expression of diphtheria toxin A-chain in mature B-cells: a potential approach to therapy of B-lymphoid malignancy. Leuk Lymphoma. 1992; 7(5-6):457-62. DOI: 10.3109/10428199209049802. View

12.

Lustig-Yariv O, Schulze E, Komitowski D, Erdmann V, Schneider T, De Groot N . The expression of the imprinted genes H19 and IGF-2 in choriocarcinoma cell lines. Is H19 a tumor suppressor gene?. Oncogene. 1997; 15(2):169-77. DOI: 10.1038/sj.onc.1201175. View

13.

Balkwill F . Tumour necrosis factor and cancer. Nat Rev Cancer. 2009; 9(5):361-71. DOI: 10.1038/nrc2628. View

14.

Gordon E, Levy J, Reed R, Petchpud W, Liu L, Wendler C . Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ. Int J Oncol. 2008; 33(4):665-75. View

15.

Kaplan R, Luettich K, Heguy A, Hackett N, Harvey B, Crystal R . Monoallelic up-regulation of the imprinted H19 gene in airway epithelium of phenotypically normal cigarette smokers. Cancer Res. 2003; 63(7):1475-82. View

16.

Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh C, Feinberg A . Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res. 2002; 62(22):6442-6. View

17.

Ayesh S, Matouk I, Schneider T, Ohana P, Laster M, de-Groot N . Possible physiological role of H19 RNA. Mol Carcinog. 2002; 35(2):63-74. DOI: 10.1002/mc.10075. View

18.

Fong M, Kakar S . Ovarian cancer mouse models: a summary of current models and their limitations. J Ovarian Res. 2009; 2(1):12. PMC: 2762470. DOI: 10.1186/1757-2215-2-12. View

19.

Louis M, Dutoit S, Denoux Y, Erbacher P, Deslandes E, Behr J . Intraperitoneal linear polyethylenimine (L-PEI)-mediated gene delivery to ovarian carcinoma nodes in mice. Cancer Gene Ther. 2005; 13(4):367-74. DOI: 10.1038/sj.cgt.7700893. View

20.

Brower V . Cancer gene therapy steadily advances. J Natl Cancer Inst. 2008; 100(18):1276-8. DOI: 10.1093/jnci/djn335. View